Your browser doesn't support javascript.
loading
Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization.
Liu, Zhiwei; Yu, Kelly J; Coghill, Anna E; Brenner, Nicole; Cao, Su-Mei; Chen, Chien-Jen; Chen, Yufeng; Doolan, Denise L; Hsu, Wan-Lun; Labo, Nazzarena; Middeldorp, Jaap M; Miley, Wendell; Simon, Julia; Wang, Cheng-Ping; Waterboer, Tim; Whitby, Denise; Xie, Shang-Hang; Ye, Weimin; Hildesheim, Allan.
Afiliación
  • Liu Z; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA zhiwei.liu@nih.gov.
  • Yu KJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • Coghill AE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • Brenner N; Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Cao SM; Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Chen CJ; Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Chen Y; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Doolan DL; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Hsu WL; Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Labo N; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Middeldorp JM; Viral Oncology Section, AIDS and Cancer Virus Program, Leidos-Biomedical, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Miley W; Department of Pathology, VU University Medical Center, Amsterdam, Netherlands.
  • Simon J; Viral Oncology Section, AIDS and Cancer Virus Program, Leidos-Biomedical, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Wang CP; Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Waterboer T; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Whitby D; Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
  • Xie SH; Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ye W; Viral Oncology Section, AIDS and Cancer Virus Program, Leidos-Biomedical, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Hildesheim A; Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
J Clin Microbiol ; 57(11)2019 11.
Article en En | MEDLINE | ID: mdl-31434722
IgA antibodies targeting Epstein-Barr virus (EBV) have been proposed for screening for nasopharyngeal carcinoma (NPC). However, methods differ, and the antigens used in these assays differ considerably between laboratories. To enable formal comparisons across a range of established EBV serology assays, we created a panel of 66 pooled serum samples and 66 pooled plasma samples generated from individuals with a broad range of IgA antibody levels. Aliquots from these panels were distributed to six laboratories and were tested by 26 assays measuring antibodies against VCA, EBNA1, EA-EBNA1, Zta, or EAd antigens. We estimated the correlation between assay pairs using Spearman coefficients (continuous measures) and percentages of agreement (positive versus negative, using predefined positivity cutoffs by each assay developer/manufacturer). While strong correlations were observed between some assays, considerable differences were also noted, even for assays that targeted the same protein. For VCA-IgA assays in serum, two distinct clusters were identified, with a median Spearman coefficient of 0.41 (range, 0.20 to 0.66) across these two clusters. EBNA1-IgA assays in serum grouped into a single cluster with a median Spearman coefficient of 0.79 (range, 0.71 to 0.89). Percentages of agreement differed broadly for both VCA-IgA (12% to 98%) and EBNA1-IgA (29% to 95%) assays in serum. Moderate-to-strong correlations were observed across assays in serum that targeted other proteins (correlations ranged from 0.44 to 0.76). Similar results were noted for plasma. We conclude that standardization of EBV serology assays is needed to allow for comparability of results obtained in different translational research studies across laboratories and populations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Virales / Pruebas Serológicas / Técnicas de Laboratorio Clínico / Infecciones por Virus de Epstein-Barr / Laboratorios / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Microbiol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Virales / Pruebas Serológicas / Técnicas de Laboratorio Clínico / Infecciones por Virus de Epstein-Barr / Laboratorios / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Microbiol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos